How Moderna Makes its Money: Revenue Breakdown (FY2024)

How Does Moderna Make its Money?

Moderna Inc. (NASDAQ: MRNA) generated $3.24 billion in total revenue in fiscal year 2024 — a -53% decline from FY2023’s $6.8B and a -82% collapse from FY2022’s $18.4B peak — as COVID-19 vaccine demand transitioned from pandemic mass campaigns to endemic seasonal boosters. Moderna’s entire commercial revenue currently flows from a single primary product: Spikevax, its mRNA-based COVID-19 vaccine. In 2024, Moderna launched its second commercial product — mRESVIA, the first mRNA-based RSV vaccine for adults 60+ — but first-year revenues were modest ($0.15B).

Moderna is simultaneously a commercial pharmaceutical company (generating real vaccine revenue) and a pre-profitability R&D platform company (spending $4.7B annually on a pipeline of 40+ mRNA programs spanning infectious diseases, oncology, rare diseases, and autoimmune conditions). The company is not currently profitable: it burned approximately $3.6B in net losses in FY2024, funded by the $10.8B cash stockpile built from COVID vaccine windfall revenues of 2021–2022. The central investment thesis — and the central risk — is whether the mRNA platform can produce enough blockbuster products before the cash runway runs out.

The technology underlying all of Moderna’s products is messenger RNA (mRNA): synthetic genetic instructions that teach human cells to produce a specific protein (an antigen), triggering an immune response without using live or inactivated pathogens. This platform is faster to develop than traditional vaccines (Moderna went from mRNA sequence to Phase 3 COVID vaccine trial in ~63 days), easier to update for new variants, and theoretically applicable to virtually any disease where you want to instruct the body to produce a specific protein — making it one of the most potentially transformative platform technologies in medicine.

Key Takeaways

• Moderna generated $3.24B in FY2024 revenue, down -53% from FY2023 and -82% from the FY2022 peak of $18.4B — the COVID vaccine revenue collapse is the defining financial fact of 2023–2024
• Spikevax (COVID-19 vaccine) remains essentially the only commercial revenue source; the COVID vaccine market has permanently shifted from pandemic mass-vaccination campaigns to an annual seasonal respiratory booster market estimated at $3–6B total market size (shared with Pfizer/BioNTech and Novavax)
• Net loss: -$3.6B in FY2024 — Moderna is spending $4.7B in R&D on a pipeline of 40+ programs while generating $3.2B in revenue; R&D spending exceeds total revenue, a structural deficit funded entirely by COVID windfall reserves
• Cash & investments: ~$9.5–10.8B — the COVID era surplus gives Moderna runway through approximately 2027–2028 without additional financing; every year without a new blockbuster approval narrows that runway
• mRESVIA (RSV vaccine) — FDA-approved May 2024, the first mRNA-based RSV vaccine; generated ~$150M in FY2024 first-year revenue; competes with GSK’s Arexvy and Pfizer’s Abrysvo in the adult RSV market; important proof of platform beyond COVID but not yet material to financials
• Personalized cancer vaccine (mRNA-4157/V940 with Merck) — the highest-optionality program in Moderna’s pipeline; a customized mRNA vaccine targeting each patient’s tumor-specific mutations, used in combination with Merck’s Keytruda (pembrolizumab); Phase 3 trial in high-risk melanoma; if successful, this redefines what Moderna is as a company
• Cost restructuring underway: Moderna announced $1B+ in targeted cost savings (2024–2027), including workforce reductions and R&D program prioritization; the goal is to reduce annual cash burn and extend runway while advancing the highest-priority pipeline programs

Moderna (MRNA) Business Model

Moderna operates as a mRNA platform biotechnology company monetizing its technology through vaccine and therapeutic product sales. Its economics differ fundamentally from traditional pharmaceutical companies, software companies, or consumer businesses. There is no perfect business model analog — the closest framework is a platform R&D company that converts large upfront scientific investment into proprietary products with durable pricing power once approved.

How mRNA economics work:

Traditional vaccine development uses weakened or inactivated pathogens, or recombinant protein antigens — processes that require complex biological manufacturing, long development timelines (10–15 years), and large capital investments in manufacturing infrastructure. mRNA sidesteps all of this: instead of producing the antigen externally and injecting it, mRNA vaccines deliver genetic instructions that cause the patient’s own cells to produce the antigen temporarily. The mRNA itself can be manufactured in a standardized chemical synthesis process — the same bioreactor equipment can produce virtually any mRNA sequence, just by changing the digital genetic code.

This gives Moderna several structural advantages:

• Speed — From target sequence selection to clinical-grade material, Moderna can move in weeks to months rather than years
• Updatability — Updating a vaccine for a new pathogen variant requires changing the genetic code digitally, not redesigning a biological manufacturing process (demonstrated with COVID variant-specific booster updates)
• Manufacturing scalability — The same manufacturing infrastructure produced COVID vaccines and now produces RSV vaccines; the marginal cost of retooling for a new product is far lower than traditional vaccines
• Breadth of application — mRNA can theoretically encode any protein, opening applications in oncology (cancer neoantigens), rare diseases (enzyme replacement), and cardiovascular disease — not just infectious diseases

Revenue model: government and commercial contracts

Moderna sells vaccines through three channels:

1. Government procurement contracts — direct purchases by national governments and health authorities (CDC, NHS, European Commission); these tend to be large fixed-price contracts with known volumes; COVID vaccine revenue was primarily this model (e.g., the U.S. government’s $6B+ advance purchase commitments in 2021)
2. Commercial market — as COVID transitioned to an endemic seasonal vaccine in 2023, distribution shifted to commercial pharmacies (Walgreens and CVS are major distributors), private insurers, and physicians; commercial pricing is higher than government contract pricing but volumes are smaller and less predictable
3. Grants and collaborative research funding — BARDA (Biomedical Advanced Research and Development Authority) and DARPA have provided grant funding for Moderna’s pandemic preparedness programs; this revenue is small (~$100–200M/year) but non-dilutive

COVID vaccine pricing power:

Moderna’s Spikevax transitioned from $20–25/dose under government pandemic contracts to $130+ per dose in the U.S. commercial market in FY2023–2024. This pricing reflects the shift from emergency government procurement (price-negotiated at scale) to commercial insurance-covered annual boosters. At $130+/dose, the revenue per dose is dramatically higher — but total doses administered collapsed as booster uptake rates fell to 15–25% of the eligible U.S. population annually, far below pandemic-era vaccination rates.

Moderna Competitors

COVID-19 vaccine competitors:

• Pfizer — Pfizer/BioNTech’s Comirnaty mRNA vaccine is Moderna’s most direct competitor; Pfizer had a larger global supply footprint and stronger commercial infrastructure during the pandemic era; in the endemic commercial market, Comirnaty and Spikevax compete for the same pharmacy shelf and physician recommendation; Pfizer’s COVID vaccine revenue also declined sharply (from $37B peak to ~$5B in 2024) but Pfizer has more revenue diversification across oncology, rare disease, and other therapeutics to absorb the decline

RSV vaccine competitors:

• Pfizer Abrysvo — traditional protein subunit RSV vaccine; approved for adults 60+ and pregnant women (to protect newborns); Pfizer had first-mover advantage in the maternal RSV indication
• GSK Arexvy — recombinant protein RSV vaccine with adjuvant; also approved for adults 60+; GSK had significant RSV research history and strong commercial relationships with physicians; the RSV adult market is currently split roughly three ways between Arexvy, Abrysvo, and mRESVIA

Oncology pipeline competition:

• Merck — Moderna’s collaborator (not competitor) on the personalized cancer vaccine; Merck’s Keytruda is the world’s best-selling cancer drug (~$25B/year); the combination of mRNA-4157 neoantigens + Keytruda checkpoint inhibitor is the core oncology bet
• Regeneron — Regeneron’s Libtayo and pipeline programs compete in the melanoma immunotherapy space; any Moderna personalized cancer vaccine approval would enter a crowded immuno-oncology market

mRNA platform competitors:

• BioNTech (BNTX) — Pfizer’s COVID vaccine partner; BioNTech has its own pipeline of mRNA cancer vaccines and infectious disease programs; it’s the most direct platform-level competitor; BioNTech’s individualized neoantigen vaccine program (BNT111, BNT122) competes directly with Moderna/Merck’s mRNA-4157 in the cancer vaccine space
• CureVac — German mRNA company; lower profile but has mRNA vaccine programs in development
• Traditional large pharma vaccine divisions (Johnson & Johnson, Sanofi, Merck & Co.) — all investing in mRNA capabilities, either organically or through partnerships

For financial context on how large pharma companies handle declining flagship product revenues and pipeline transitions, see Eli Lilly vs Novo Nordisk.

Revenue Breakdown

Financial data sourced from Moderna FY2024 Annual Report (10-K).

Spikevax (COVID-19 Vaccine) — 95% of Revenue

The COVID-19 revenue collapse tells the story of the pandemic vaccine market in numbers:

The $15.3B revenue decline from FY2022 to FY2024 is one of the most dramatic top-line collapses in pharmaceutical history — not because the product failed, but because the pandemic emergency that created unprecedented demand is over. The COVID vaccine is now a seasonal respiratory product, similar to the flu vaccine, competing for consumer mindshare as an annual fall booster. Unlike flu vaccines (which have 40–50% adult uptake in the U.S.), COVID booster uptake in 2023–2024 has been approximately 15–25% of eligible adults — a much smaller market than pandemic-era.

Moderna’s FY2025 guidance targeted $2.5B–$3.5B in COVID vaccine revenue — implying the current run-rate is roughly the floor, with potential for modest recovery if booster uptake rates improve or if the flu+COVID combination vaccine (mRNA-1083) launches.

mRESVIA (RSV Vaccine) — $0.15B (First Year)

FDA approved in May 2024 for adults 60+, mRESVIA is Moderna’s first commercial product beyond COVID. RSV is a respiratory virus that causes approximately 60,000–120,000 hospitalizations and 6,000–10,000 deaths annually among U.S. adults 60+. The adult RSV vaccine market (launched only in 2023, when GSK’s Arexvy was first approved) is still early — physician and consumer awareness of RSV vaccine recommendations is lower than for flu or COVID.

mRESVIA’s first-year revenue of ~$150M reflects launch-year dynamics: limited formulary coverage in some insurance plans, physician education lag, and competition from established RSV vaccines from GSK and Pfizer. The market opportunity is real — the adult RSV vaccine market is estimated at $2–4B total addressable at steady state — but mRESVIA needs to prove differentiation (mRNA delivery advantages vs. established protein subunit vaccines) to take durable market share.

Grant Revenue — Near Zero

BARDA and DARPA grant funding collapsed in FY2024 as pandemic preparedness funding dried up. Moderna has applied for new grants tied to next-generation pandemic preparedness (avian flu, pandemic flu), but this revenue line is not a reliable source of meaningful income.

Revenue by Geography

The U.S. commercial market transition (from government contracts to insurance-covered commercial sales at $130+/dose) has been more resilient than international markets, where government procurement pricing remained lower and booster programs varied significantly by country.

Revenue Trend (3-Year)

The trajectory is stark: Moderna generated $8.4B in net profit in FY2022 — then burned -$4.7B in FY2023 and -$3.6B in FY2024. The cumulative swing from FY2022 peak profitability to post-pandemic losses is approximately -$12B in net income over two years. The cash reserves absorb this — but not indefinitely. Positively, cash burn improved from -$4.7B (FY2023) to -$3.6B (FY2024), reflecting cost restructuring beginning to take effect.

Moderna (MRNA) Income Statement

Financial data sourced from Moderna SEC filings.

Note on FY2023 vs FY2024 net loss: Despite a larger operating loss in FY2024 (-$3.19B vs -$1.39B in FY2023), the net loss was smaller (-$3.63B vs -$4.71B) because FY2023 included significant inventory write-downs and purchase commitment charges (~$1.4B) related to COVID vaccine manufacturing obligations that were not repeated at the same scale in FY2024. Adjusting for those one-time items, the underlying operational trajectory shows gradual cost improvement.

Key Financial Metrics

• Gross Margin: 61.7% — Stronger than the existing page suggested. At $3.24B revenue and $1.24B cost of sales, gross margin recovered to ~62% as inventory write-downs and manufacturing inefficiencies from the pandemic transition normalized. This compares favorably to traditional vaccine manufacturers (~50–60% gross margins) and reflects the mRNA platform’s manufacturing cost structure. Peak gross margin during COVID was ~75%+ when manufacturing volumes were at maximum efficiency — a margin that may return if mRNA pipeline products scale

• Operating Margin: -98% — Deeply negative, reflecting that R&D spending ($4.7B) alone exceeds total revenue ($3.2B). This is not unusual for a biotech company transitioning from one commercial product to a broader pipeline — but the scale of the deficit, and the shrinking cash buffer, creates urgency for pipeline successes. Operating margin will remain deeply negative until either (a) COVID revenue stabilizes and RSV/combo vaccine revenues scale, or (b) new pipeline approvals generate significant new revenue streams

• Operating Leverage — Moderna’s cost structure is heavily front-loaded in R&D (fixed/semi-fixed regardless of revenue), meaning operating losses expand rapidly when revenue declines but would narrow quickly if new products are approved and ramp commercially. Each $1B of new approved-product revenue would flow to operating income at approximately 60%+ incremental margin (after cost of goods), given the fixed R&D spending base is already funded

• Free Cash Flow: approximately -$3.5B to -$4.0B — Cash burn is the critical metric. Moderna generated ~$9.5B in cash and investments at year-end 2024. At ~$3.5–4.0B annual cash burn (after factoring in capital expenditures, working capital, and operating losses), the runway extends to approximately 2027–2028 without new product approvals or additional financing. A successful mRNA-4157 cancer vaccine approval (which carries milestone and royalty revenue from Merck) or broad mRNA-1083 flu+COVID combo approval could materially extend the runway

• Stock-Based Compensation: ~$0.7–0.8B — Significant for a company of Moderna’s current revenue scale (~22% of revenue); reflects the talent requirements for running a 40+ program pipeline and retaining scientific leadership; partially offset by GAAP adjustments in non-GAAP reporting; will decline as a percentage of revenue if the pipeline succeeds and revenue scales

• Price-to-Sales Ratio — At an ~$18B market cap on $3.24B revenue, Moderna trades at roughly 5.5x P/S — elevated for a declining-revenue business but reflective of the optionality value embedded in the pipeline. The market is pricing in some probability of pipeline success (particularly mRNA-4157 cancer vaccines, flu+COVID combo, CMV vaccine) beyond the current Spikevax/mRESVIA commercial base

Is Moderna Profitable?

No — Moderna reported a net loss of $3.63 billion in FY2024 on $3.24B in revenue. R&D spending alone ($4.71B) exceeded total revenue — a dynamic that has persisted since 2022 when COVID revenues began declining. Moderna was highly profitable during the COVID peak (FY2022: $8.4B net income), but that profitability was concentrated in two years and has been almost entirely deployed into the pipeline investment.

The path to profitability requires at least one and ideally two of the following:

1. COVID vaccine revenue stabilizes at $2.5–3.5B/year and RSV (mRESVIA) scales to $0.5–1.0B/year — combined, this brings total revenue toward $4–5B, reducing the operating loss but not eliminating it
2. mRNA-1083 (flu+COVID combo) approval — potentially a $2–4B incremental revenue opportunity if it achieves meaningful market penetration in the large flu vaccine market (Sanofi Fluzone, AstraZeneca FluMist are incumbent leaders)
3. mRNA-4157 cancer vaccine approval — milestone payments from Merck plus royalties on any approved product; the financial impact depends on deal structure but could add hundreds of millions in royalty revenue at meaningful margins
4. CMV vaccine (mRNA-1647) approval — cytomegalovirus is a massive unmet need (no approved vaccine), particularly in congenital infection prevention; a CMV vaccine could be a multi-billion dollar product

Without at least two pipeline approvals in the 2025–2027 window, Moderna would need to raise additional capital (dilutive equity offering) or significantly slash R&D spending (which would delay or derail the pipeline).

The mRNA Pipeline: Moderna’s Bet on Platform Value

Moderna’s pipeline spans four therapeutic areas:

Infectious Diseases (most advanced):

• mRNA-1083 (Flu + COVID combo) — Phase 3; a single annual shot targeting both influenza and COVID-19; if approved, this would be transformative for Moderna’s commercial relevance; the flu vaccine market is ~$7B globally (Sanofi, GSK, AstraZeneca are leaders); a combination shot simplifies vaccination for patients and physicians; Phase 3 efficacy results expected in 2025; this is the single most important near-term commercial catalyst after COVID seasonalization
• mRESVIA / Next-Gen RSV (mRNA-1345) — approved (first gen); second-gen formulation for improved immunogenicity in development; Moderna is also pursuing RSV in younger adults, pediatric populations (not yet approved), and in combination products
• CMV Vaccine (mRNA-1647) — Phase 3; cytomegalovirus causes 30,000–40,000 congenital infections annually in the U.S., leading to deafness, developmental delays, and death in newborns; no approved vaccine exists; this is potentially Moderna’s largest pure disease-burden opportunity; Phase 3 enrollment in women of childbearing age is ongoing; if effective, CMV vaccine could be a $2–4B+ product
• Avian Flu (H5N1) mRNA vaccine — in development; BARDA has funded early work; the mRNA platform’s speed advantage is maximally valuable for pandemic preparedness scenarios

Oncology (transformative optionality):

• mRNA-4157/V940 (Individualized Neoantigen Vaccine) + Merck Keytruda — Phase 3 in high-risk resected melanoma; this is a customized vaccine built from sequencing each patient’s tumor DNA, identifying tumor-specific mutations (neoantigens), and encoding up to 34 neoantigen mRNA sequences in a personalized vaccine manufactured in ~6 weeks; Phase 2b data showed 49% reduction in recurrence/death vs. Keytruda alone in melanoma; if Phase 3 confirms this benefit, this represents a new category of cancer treatment — and Moderna as a manufacturing platform for personalized medicine at scale; Phase 3 results could read out 2025–2027

Rare Diseases:

• mRNA-3705 (Methylmalonic Acidemia) — early phase; rare metabolic disorder; uses mRNA to deliver functional enzyme replacement instructions to the liver; proof-of-concept for mRNA in rare diseases beyond vaccines

Cardiovascular:

• mRNA-0184 (Relaxin) — early stage; heart failure program; expanding the platform beyond immunology

What to Watch

1. mRNA-1083 (flu+COVID combo) Phase 3 results — The highest near-term commercial catalyst. If Phase 3 demonstrates non-inferior flu efficacy plus non-inferior COVID efficacy vs. separate vaccines, an FDA approval would position Moderna for the ~$7B global flu market plus a retained share of COVID booster revenue in a single annual shot. Positive data (expected 2025) would be the single largest near-term stock catalyst. Any failure or safety signal would significantly pressure the revenue outlook

2. mRNA-4157 Phase 3 melanoma results — The single most transformative catalyst in the entire Moderna pipeline. Phase 2b data was extraordinary (49% relative risk reduction in recurrence when added to Keytruda). Phase 3 must replicate this in a larger population. If successful, this validates the personalized cancer vaccine concept and Moderna as a scalable platform for individualized medicine — which could justify a dramatic re-rating of the company’s long-term value. If Phase 3 fails (or shows smaller benefit), this removes the largest source of oncology optionality

3. Cash burn trajectory and cost restructuring progress — Moderna targeted $1B+ in cost savings by 2027 through workforce reductions, R&D program prioritization (cutting or partnering lower-priority programs), and manufacturing efficiency. Track quarterly operating cash outflows vs. the $3.5–4.0B annual burn rate target. If cash burn remains above $4.0B/year without revenue recovery, a capital raise becomes likely within 2 years; if burn drops toward $2.5–3.0B through cost cuts, runway extends materially

4. CMV vaccine Phase 3 results — Phase 3 in women of childbearing age has the potential to produce results in 2026–2027. CMV is a massive unmet medical need with no existing vaccine — a successful approval would give Moderna a near-monopoly product in a market with no competitor. Market size estimates for a maternal/universal CMV vaccine range from $2–5B+. This is the “sleeper” pipeline program — less discussed than cancer vaccines but potentially the largest pure commercial opportunity in Moderna’s pipeline

5. mRESVIA market share in RSV — Track quarterly RSV vaccine revenue vs. GSK Arexvy and Pfizer Abrysvo in CDC ACIP recommendation adherence and commercial pharmacy uptake. Moderna needs mRESVIA to grow from $150M (FY2024) toward $500M+ to contribute meaningfully to the revenue recovery. Any ACIP preferential recommendation for mRESVIA vs. competitors (based on immunogenicity advantages) would be a significant catalyst

6. COVID booster uptake rates in fall 2025 — Annual COVID booster season (September–December) is now Moderna’s primary revenue concentration point. Track CDC data on COVID vaccine uptake rates among eligible adults; any sustained improvement from the 15–25% current range toward 30–35% could add $0.5–1.0B in Spikevax revenue relative to current guidance. Partnership with Pfizer or any shift in ACIP recommendation language could also affect market share

Moderna (MRNA) Financial Summary

Moderna (NASDAQ: MRNA) generated $3.24 billion in total revenue in FY2024 — a -53% decline from FY2023 and -83% from the FY2022 peak of $18.4B — as COVID-19 vaccine revenue collapsed from pandemic emergency demand to endemic seasonal levels. Net loss was -$3.63B as R&D spending ($4.71B) exceeded total revenue. Moderna holds approximately $9.5B in cash and investments, providing runway to approximately 2027–2028 at current burn rates, with ongoing cost restructuring targeting $1B+ in savings by 2027. The commercial portfolio is transitioning: Spikevax remains the revenue anchor, mRESVIA (RSV) launched in 2024 as the first beyond-COVID product, and the flu+COVID combination vaccine (mRNA-1083) is the most important near-term commercial catalyst. The personalized cancer vaccine (mRNA-4157 with Merck) in Phase 3 melanoma represents the company’s most transformative optionality — potentially validating Moderna as a platform for individualized medicine at scale. The core risk is timing: whether the pipeline can generate blockbuster approvals before the cash runway forces dilutive financing or R&D cuts.

For the competitive pharmaceutical landscape, see Eli Lilly vs Novo Nordisk and the Biotechnology Sector analysis. For vaccine distribution context, see Walgreens vs CVS.